Sun Pharma Advanced Research Co Stock Screener | Share Price & Fundamental Analysis

SPARC Pharmaceuticals
Share Price NSE
₹126.38
▲ 3.76 (3.07%)
2026-04-07 00:00:00
Share Price BSE
₹126.25
▲ 3.35 (2.73%)
2026-04-07 00:00:00
Track Sun Pharma Advanced Research Co share price live with TickJournal's free stock screener. Analyze Sun Pharma Advanced Research Co share price history trends and compare 52-week high low levels. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Sun Pharma Advanced Research Co Market Cap ₹4,025.74 Cr.
SPARC P/E Ratio (TTM) -14.57
Sun Pharma Advanced Research Co P/B Ratio -11.33
EPS (TTM) ₹-10.55
Dividend Yield -
Debt to Equity -
SPARC 52 Week High ₹198.54
Sun Pharma Advanced Research Co 52 Week Low ₹108.71
Operating Margin -196.00%
Profit Margin -222.22%
SPARC Revenue (TTM) ₹27.00
EBITDA ₹-53.00
Net Income ₹-60.00
Total Assets ₹336.00
Total Equity ₹-217.00

Sun Pharma Advanced Research Co Share Price History - Stock Screener Chart

Screen SPARC historical share price movements with interactive charts. Analyze price trends and patterns.

Sun Pharma Advanced Research Co Company Profile - Fundamental Screener

Screen Sun Pharma Advanced Research Co company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for SPARC shares.
Sun Pharma Advanced Research Company Ltd. (SPARC) is an India-based clinical-stage biopharmaceutical company focused on developing new drugs and delivery systems. It specializes in creating therapeutics in oncology, neurology, and immunology. SPARC's key projects include vodobatinib for chronic myelogenous leukemia and neurodegenerative diseases, an anti-MUC-1 antibody-drug conjugate for multiple cancers,...more
Sector Healthcare
Industry Pharmaceuticals
Sub-Sector Pharmaceuticals
Segment E
Chairperson/CEO Dilip S Shanghvi
ISIN INE232I01014

Sun Pharma Advanced Research Co Balance Sheet Screener

Screen SPARC balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
Item 2025 2024 2023
Assets
Total Assets 336 515 830
Current Assets 26 269 455
Fixed Assets 99 108 106
Liabilities
Total Liabilities 0 0 0
Current Liabilities 178 124 138
Non-Current Liabilities 0 0 0
Shareholders' Equity
Total Equity -217 126 513
Share Capital 33 33 33
Reserves & Surplus -249 93 480

Sun Pharma Advanced Research Co Income Statement Screener - Profit & Revenue Analysis

Screen Sun Pharma Advanced Research Co income statement and profit fundamentals. Analyze SPARC quarterly results, revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Sun Pharma Advanced Research Co share price evaluation.
Item 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun 2024-Sept 2024-Dec 2023-Mar 2023-Jun 2023-Sept 2023-Dec
Revenue 27 19 8 8 21 18 13 15 58 34 30 20
Expenses 80 62 74 77 122 110 116 89 137 126 113 117
EBITDA -53 -43 -66 -69 -101 -92 -103 -74 -79 -92 -83 -96
Operating Profit % -196.00% -540.00% -836.00% -817.00% -639.00% -555.00% -800.00% -494.00% -188.00% -427.00% -432.00% -740.00%
Depreciation 3 3 3 3 3 3 3 3 3 3 3 3
Interest 5 6 8 9 1 1 1 3 0 0 0 0
Profit Before Tax -61 -52 -76 -80 -105 -96 -107 -79 -82 -95 -86 -100
Tax -1 0 0 0 0 0 0 0 0 0 0 0
Net Profit -60 -52 -76 -80 -106 -96 -107 -80 -82 -95 -86 -100
EPS -1.84 -1.60 -2.34 -2.48 -3.26 -2.96 -3.31 -2.45 -2.55 -2.94 -2.66 -3.07

Sun Pharma Advanced Research Co Cash Flow Screener - Liquidity Fundamentals

Screen SPARC cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
Item 2025-March 2024-March 2023-March
Operating Activities -360 -429 -69
Investing Activities 158 392 -548
Financing Activities 199 42 617
Net Cash Flow -3 5 -1

Sun Pharma Advanced Research Co Shareholding Pattern Screener

See Sun Pharma Advanced Research Co shareholding pattern with promoter, FII, and DII holdings. Check Sun Pharma Advanced Research Co promoter holding and ownership changes for SPARC on TickJournal.
Item 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun 2024-Sept 2024-Dec
Promoter Holding 65.67% 65.67% 65.67% 65.67% 65.67% 65.67% 65.67% 65.67%
FII Holding 1.45% 1.47% 1.76% 2.04% 3.23% 2.64% 2.15% 2.23%
DII Holding 1.13% 0.97% 1.05% 0.78% 0.82% 0.18% 0.23% 0.64%
Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 18.99% 19.15% 18.94% 19.20% 16.11% 18.91% 19.20% 18.89%
Other Holding 12.76% 12.73% 12.59% 12.30% 14.17% 12.60% 12.75% 12.58%
Shareholder Count 142,864 140,724 136,997 144,810 102,743 125,184 128,205 131,034

Sun Pharma Advanced Research Co Share Dividend Screener - Share Yield Analysis

Check Sun Pharma Advanced Research Co dividend history with payout and yield data. View Sun Pharma Advanced Research Co dividend details including ex-dates and amounts for SPARC stock.
No dividends declared by Sun Pharma Advanced Research Co.

Sun Pharma Advanced Research Co Stock Index Membership

See which indices include Sun Pharma Advanced Research Co stock. Check SPARC index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE 1000
BSE INDEX BSE HC
BSE INDEX BSE500
BSE INDEX MSL400
BSE INDEX SML250
BSE INDEX SMLCAP
NIFTY MICROCAP250
NIFTY TOTAL MKT
NIFTY500 LARGEMIDSMALL EQUAL CAP WEIGHTED

Sun Pharma Advanced Research Co Market Events Screener - Corporate Actions

Get Sun Pharma Advanced Research Co corporate actions including splits, bonuses, and buybacks. Check Sun Pharma Advanced Research Co stock events that may affect SPARC share price.
Announcement Date Record Date Event Type Information Price Impact
2026-02-09 2026-02-09 Extraordinary General Meeting NA 2.66%
2026-02-09 2026-02-09 Quarterly Result Announcement NA 4.31%
2025-11-10 2025-11-10 Quarterly Result Announcement NA -2.74%
2025-08-12 2025-08-12 Annual General Meeting NA -9.42%
2025-08-04 2025-08-04 Quarterly Result Announcement NA -1.45%
2025-05-19 2025-05-19 Quarterly Result Announcement NA 14.45%
2025-02-10 2025-02-10 Quarterly Result Announcement NA 0.79%
2024-11-04 2024-11-04 Quarterly Result Announcement NA 4.07%
2024-08-12 2024-08-12 Annual General Meeting NA -12.92%
2016-03-16 2016-03-17 Rights 5:116 -

Sun Pharma Advanced Research Co Competitors Screener - Peer Comparison

Screen SPARC competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 406,351 37.86 54,729 9.71% 10,980 37.98
Divis Laboratories 155,472 63.26 9,712 18.67% 2,191 33.24
Torrent Pharmaceuticals 134,945 61.20 11,539 6.99% 1,911 32.75
Lupin 103,954 22.26 22,910 13.74% 3,306 47.35
Dr Reddys Laboratories 101,601 18.27 33,741 16.73% 5,725 39.36
Cipla 96,320 21.31 28,410 7.12% 5,291 26.86
Zydus Life Science 86,964 17.29 23,511 18.55% 4,615 41.42
Mankind Pharma 82,499 45.81 12,744 20.90% 2,007 41.40
Aurobindo Pharma 77,462 22.37 32,346 9.43% 3,484 64.38
Alkem Laboratories 62,867 25.87 13,458 3.70% 2,216 42.54

Sun Pharma Advanced Research Co Company Announcements - News Screener

Screen SPARC latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
Date Update Actions
2026-04-07 Announcement under Regulation 30 (LODR)-Change in Management -
2026-04-01 Announcement under Regulation 30 (LODR)-Change in Management -
2026-03-31 Clarification Regarding Increase In Volume -
2026-03-31 Clarification sought from Sun Pharma Advanced Research Company Ltd -
2026-03-31 Closure of Trading Window -
2026-02-24 Addendum To The Valuation Report Issued On January 14 2026 -
2026-02-10 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-02-09 Shareholder Meeting / Postal Ballot-Outcome of EGM -
2026-02-09 Unaudited Standalone And Consolidated Financial Results For The Quarter And Nine Months Ended December 31 2025 -
2026-02-09 Board Meeting Outcome for For Approval Of Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2025 -
2026-02-03 Board Meeting Intimation for Approval Of Unaudited Financial Results For Quarter And Nine Months Ended December 31 2025 -
2026-02-03 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-02-02 Clarification Regarding Increase In Volume -
2026-02-02 Clarification sought from Sun Pharma Advanced Research Company Ltd -
2026-01-30 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-01-29 Corrigendum To The Notice Of Extra Ordinary General Meeting Of The Company Scheduled To Be Held On Monday February 09 2026 -
2026-01-17 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-01-16 Notice Of Extra Ordinary General Meeting Of Sun Pharma Advanced Research Company Limited -
2026-01-16 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-01-15 Announcement under Regulation 30 (LODR)-Newspaper Publication -